ProPhase Labs (ProPhase Labs) EPS (Basic) : $-0.98 (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is ProPhase Labs EPS (Basic)?

ProPhase Labs's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.51. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.98.

ProPhase Labs's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.51. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.98.

ProPhase Labs's EPS without NRI for the three months ended in Dec. 2023 was $-0.51. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -0.98.

During the past 12 months, ProPhase Labs's average EPS without NRIGrowth Rate was -195.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -45.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, ProPhase Labs's highest 3-Year average EPS without NRI Growth Rate was 30.00% per year. The lowest was -45.40% per year. And the median was -12.60% per year.

ProPhase Labs EPS (Basic) Historical Data

The historical data trend for ProPhase Labs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProPhase Labs EPS (Basic) Chart

ProPhase Labs Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-0.27

-0.18

0.41

1.17

-0.98

ProPhase Labs Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EPS (Basic)	Get a 7-Day Free Trial															-0.16	0.03	-0.20	-0.30	-0.51

ProPhase Labs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

ProPhase Labs's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-16.782	-	0)	/	17.207
	=	-0.98

ProPhase Labs's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-8.751	-	0)	/	18.056
	=	-0.48

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98

ProPhase Labs (NAS:PRPH) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

ProPhase Labs EPS (Basic) Related Terms

Thank you for viewing the detailed overview of ProPhase Labs's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

ProPhase Labs (ProPhase Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » ProPhase Labs Inc (NAS:PRPH) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

711 Stewart Avenue, Suite 200, Garden City, NY, USA, 11530

Website

https://www.prophaselabs.com

ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Executives

Morse Robert A. Jr.	officer: Controller	711 STEWART AVENUE, SUITE 200, GARDEN CITY NY 11530
Billy Joe White	officer: Chief Financial Officer	191 OTTO ST., PORT TOWNSEND WA 98368
Jason Michael Barr	director	902 BROADWAY, 15TH FLOOR, NEW YORK NY 10010
Louis Md Gleckel	10 percent owner	C/O PROHEALTH CARE ASSOCIATES LLP, 2800 METRUS AVE, LAKE SUCCESS NY 11042
Ted William Karkus	10 percent owner	188 HEWLETT NECK ROAD, WOODMERE NY 11598
Warren Hirsch	director	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Monica L. Brady	officer: Chief Accounting Officer	621 N. SHADY RETREAT ROAD, DOYLESTOWN PA 18901
Cuddihy Robert V Jr	officer: Chief Operating Officer	PARKER DURYEE ET AL, 529 FIFTH AVE 8TH FL, NEW YORK NY 10017
Braden Michael Leonard	10 percent owner	156 S. FIRST STREET, ZIONSVILLE IN 46077
Mark S Leventhal	10 percent owner	THE BEACON COMPANIES, 50 FEDERAL STREET, BOSTON MA 02468
Mark Shawn Frank	director	104 WHISPER WOOD COURT, WRIGHTSTOWN PA 18940
James T Mccubbin	director
Mark A. Burnett	10 percent owner	40 HEMLOCK DRIVE, ROSLYN NY 11576
Guy J Quigley	director, 10 percent owner, officer: Chairman, President, CEO	C/O THE QUIGLEY CORP KELLS BUILDINGS, 621 SHADY RETREAT RD P O BOX 1349, DOYLESTOWN PA 18901
John Deshazo	10 percent owner	17 WOLCOTT COURT, BOSTON MA 02136